Investment Opportunity
The Numbers
Tell the Story
Tell the Story
Africa's first fully integrated medical cannabis ecosystem — at the intersection of health-tech, pharmaceutical, and market-creating infrastructure.
R43M
Year 1 Revenue Target
Conservative model based on 5,000 patients and 250 active prescribing doctors with R1,200 average script value.
R250M
Series A Target
Q4 2026 / Q1 2027 raise. 30% doctor scale, 25% patient acquisition, 25% international expansion, 20% R&D + GMP.
R2.16B
Year 5 Revenue Forecast
400,000+ patients. 3,000+ doctors. 3+ countries. CannaZon™ marketplace. IntroCann SaaS. Export revenue streams.
$6.3B
Global Market (2030)
Medical cannabis market projected to exceed $6.3B globally by 2030. Africa is at the frontier of this shift.
70M+
IntroCann Data Points
The largest clinical cannabis dataset in Africa. A licensing, AI-training, and research asset that compounds with every prescription.
R420M
Year 5 EBITDA
Recurring prescription-based revenue. Low patient churn. High-margin SaaS layer. Asset-light distribution infrastructure.
Milestones
The Journey So Far
-
2017CannaChi (Pty) Ltd foundedThe group's holding company is registered in South Africa (Reg No. 2017/258542/07).
-
Mar 2026Hillview Hemp JV signedJoint venture for CBD extraction and biomass on up to 48.4ha, with SynerChi as capital partner.
-
Apr 2026MediPost NDA signedDispensing and national fulfilment partnership formalised on 1 April 2026.
-
Q3 2026CannaZon™ launchAfrica's compliant medicinal cannabis marketplace platform goes live.
-
Q4 2026 – Q1 2027Series A raiseR250M raise to scale the doctor network, patient acquisition and international expansion.
Investor Relations
Request the Investor Deck
Receive the CannaChi Group investor deck and financial model, and arrange a call with the executive team.
- 🔐 Your details are protected under POPIA
- ⏱️ We usually respond within one business day